197 related articles for article (PubMed ID: 35770320)
1. Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.
Jirabanditsakul C; Dakeng S; Kunacheewa C; U-Pratya Y; Owattanapanich W
Technol Cancer Res Treat; 2022; 21():15330338221111228. PubMed ID: 35770320
[TBL] [Abstract][Full Text] [Related]
2. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
[TBL] [Abstract][Full Text] [Related]
3. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Gralewski JH; Post GR; van Rhee F; Yuan Y
Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
[TBL] [Abstract][Full Text] [Related]
4. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
[TBL] [Abstract][Full Text] [Related]
5. Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients.
Hu Y; Chen W; Wang J
Onco Targets Ther; 2019; 12():9999-10010. PubMed ID: 31819496
[TBL] [Abstract][Full Text] [Related]
6. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Tessoulin B; Moreau-Aubry A; Descamps G; Gomez-Bougie P; Maïga S; Gaignard A; Chiron D; Ménoret E; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
J Hematol Oncol; 2018 Dec; 11(1):137. PubMed ID: 30545397
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.
Bohn OL; Hsu K; Hyman DM; Pignataro DS; Giralt S; Teruya-Feldstein J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e65-8. PubMed ID: 24445188
[No Abstract] [Full Text] [Related]
8. Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias.
Rebmann Chigrinova E; Porret NA; Andres M; Wiedemann G; Banz Y; Legros M; Pollak M; Oppliger Leibundgut E; Pabst T; Bacher U
BMC Med Genomics; 2022 Sep; 15(1):203. PubMed ID: 36138464
[TBL] [Abstract][Full Text] [Related]
9. Progress in the identification of gene mutations involved in multiple myeloma.
Hu Y; Chen W; Wang J
Onco Targets Ther; 2019; 12():4075-4080. PubMed ID: 31213829
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortüm KM; Mai EK; Hanafiah NH; Shi CX; Zhu YX; Bruins L; Barrio S; Jedlowski P; Merz M; Xu J; Stewart RA; Andrulis M; Jauch A; Hillengass J; Goldschmidt H; Bergsagel PL; Braggio E; Stewart AK; Raab MS
Blood; 2016 Sep; 128(9):1226-33. PubMed ID: 27458004
[TBL] [Abstract][Full Text] [Related]
11. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.
Tang TF; Chan YT; Cheong HC; Cheok YY; Anuar NA; Looi CY; Gan GG; Wong WF
Cell Immunol; 2022 Oct; 380():104594. PubMed ID: 36081178
[TBL] [Abstract][Full Text] [Related]
12. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
13. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
Da Vià MC; Solimando AG; Garitano-Trojaola A; Barrio S; Munawar U; Strifler S; Haertle L; Rhodes N; Teufel E; Vogt C; Lapa C; Beilhack A; Rasche L; Einsele H; Kortüm KM
Oncologist; 2020 Feb; 25(2):112-118. PubMed ID: 32043788
[TBL] [Abstract][Full Text] [Related]
14. [Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].
Fan Y; Wang SJ; Liu YF; Wang C; Li YF; Wang WQ; Hao QQ; Zhang DF; Li YM; Sun H; Guo R; Chen SQ; Xie XS; Li T; Wan DM; Jiang ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):166-169. PubMed ID: 35123621
[TBL] [Abstract][Full Text] [Related]
15. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
[TBL] [Abstract][Full Text] [Related]
16. RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation.
Le Calvez B; Le Bris Y; Herbreteau G; Jamet B; Bossard C; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Antier C; Theisen O; Kraeber-Bodéré F; Le Gouill S; Béné MC; Moreau P; Touzeau C
EJHaem; 2020 Jul; 1(1):318-322. PubMed ID: 35847743
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
Ryu D; Kim HJ; Joung JG; Lee HO; Bae JS; Kim SJ; Kim H; Park WY; Kim K
Oncotarget; 2016 Jul; 7(30):47127-47133. PubMed ID: 27223072
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma clonal evolution in homogeneously treated patients.
Corre J; Cleynen A; Robiou du Pont S; Buisson L; Bolli N; Attal M; Munshi N; Avet-Loiseau H
Leukemia; 2018 Dec; 32(12):2636-2647. PubMed ID: 29895955
[TBL] [Abstract][Full Text] [Related]
19. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Agnarelli A; Chevassut T; Mancini EJ
Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm KM; Langer C; Monge J; Bruins L; Zhu YX; Shi CX; Jedlowski P; Egan JB; Ojha J; Bullinger L; Kull M; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Ann Hematol; 2015 Jul; 94(7):1205-11. PubMed ID: 25743686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
